APG-115
APG-115 is a pharmaceutical drug with 8 clinical trials. Currently 6 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
7
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
6
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
APG-115 in Salivary Gland Cancer Trial
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
Clinical Trials (8)
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
APG-115 in Salivary Gland Cancer Trial
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
APG-115 in Patients With Advanced Solid Tumors or Lymphomas
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8